

研究成果の刊行に関する一覧表

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Hosono, T.; Niwa, Y.; <u>Kondoh, M.</u>	Comparison of product features and clinical trial designs for the DTx products with the indication of insomnia authorized by regulatory authorities.	<i>Ther Innov Regul Sci</i>	58	1138-1147	2024
Tachibana, K.; Bai, L.; Sugimura, S.; Fujioka H.; Kishimoto, W.; Mizuguchi, H.; Nakase, H.; <u>Kondoh, M.</u>	Heterogenous gene expression of bicellular and tricellular tight junction-sealing components in the human intestinal tract	<i>Biol Pharm Bull</i>	47	1209-1217	2024
Ishibashi, K.; Kusakabe, T.; <u>Kondoh, M.</u>	Current application of the medical device single audit program (MDSAP) as a global regulatory reliance framework for the inspection of medical devices.	<i>Ther Innov Regul Sci</i>	58	1172-1179	2024
Hara, T.; Sato, Y.; Tanishiro, H.; Tamaki, Y.; Baba, S.;	Principles for evaluating the efficacy and safety of ceramic dental implants in Japan	<i>Ther Innov Regul Sci</i>	59	3-8	2025

Hirose, E.; Yoshida, B.; Watanabe, K.; Nishikawa, G.; Okuda, D.; Murakami, M.; Niwa, Y.; <u>Kondoh,</u> M.					
Tachibana, K., Sugimura, S., Sakimura, S., Bai, L., Aoyama, H., Takeda, H., Niwa, Y., Nagahama, M., <u>Kondoh,</u> M.	Size-selective permeation- enhancing modulation of the tight junction by receptor-binding domains of <i>Clostridium</i> <i>perfringens</i> enterotoxin and <i>Clostridium</i> <i>perfringens</i> iota-toxin.	<i>Tissue Barriers</i>			In press
Nagase, T.; Shima, N.; Maruhana, N.; Miyazawa, Y.; Yoshino, S.; Sato, J.; Yamada, H.; Shinozaki, K.; <u>Ikeda, K.</u>	Analysis and evaluation of factors contributing to the occurrence of immune-related adverse events with immune checkpoint inhibitors.	<i>Pharmazie</i>	79	163-168	2024
Yoshikai, S.; Ueda, M.; <u>Ikeda, K.</u>	Effect of morphine used to relieve dyspnea due to heart	<i>J Palliat Med</i>	27	1184-1190	2024

	failure on delirium.				
Masuda, K.; <u>Ikeda, K.</u> ; Endo, A.; Ishikawa, T.; Matsumoto T.	Building vancomycin population pharmacokinetic model for Japanese low birth weight infants in comparing it with previously reported pediatric population pharmacokinetic models.	<i>J Infect Chemother,</i>			In press